Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

BACKGROUND: Angiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, Patrick A, Nazzaro, Matthew, Pfaff, Kathleen L, Gjini, Evisa, Felt, Kristen D, Wolff, Jacquelyn O, Buchbinder, Elizabeth I, Haq, Rizwan, Sullivan, Ryan J, Lawrence, Donald P, McDermott, David F, Severgnini, Mariano, Giobbie-Hurder, Anita, Rodig, Scott J, Stephen Hodi, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593712/
https://www.ncbi.nlm.nih.gov/pubmed/34772758
http://dx.doi.org/10.1136/jitc-2021-003318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593712/
https://www.ncbi.nlm.nih.gov/pubmed/34772758
http://dx.doi.org/10.1136/jitc-2021-003318

Ejemplares similares